Takeda CEO reports tax-related ADS sale

Takeda Pharmaceutical Co Ltd President and CEO Julie So-Young Kim reported selling 89,090 American Depositary Shares on August 10, 2026 at a weighted average price of $17.10 per share.

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd President and CEO Julie So-Young Kim reported selling 89,090 American Depositary Shares on August 10, 2026 at a weighted average price of $17.10 per share. The company states this was a mandatory sale to cover taxes on vesting equity awards, leaving her with 391,489 ADS held directly.

Insider Trade Summary

Net Seller: 89,090 shares

Net Sell 1 txn

Insider Kim Julie So-Young

Role President and CEO

Sold 89,090 shs ($1.52M)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	89,090	$17.10	$1.52M

Holdings After Transaction: American Depositary Shares — 391,489 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 89,090 American Depositary Shares Weighted average sale price: $17.10 per share Shares owned after transaction: 391,489 American Depositary Shares

3 metrics

Shares sold 89,090 American Depositary Shares Mandatory sale on August 10, 2026 to cover taxes on vesting equity awards

Weighted average sale price $17.10 per share Price for American Depositary Shares sold in the reported transaction

Shares owned after transaction 391,489 American Depositary Shares Direct holdings of CEO Julie So-Young Kim following the sale

Key Terms

American Depositary Shares, weighted average price, mandatory sale to cover taxes

3 terms

American Depositary Shares financial

"The transaction involved <b>American Depositary Shares</b> of Takeda Pharmaceutical Co Ltd."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported is a <b>weighted average price</b> with details available on request."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

mandatory sale to cover taxes financial

"Represents a <b>mandatory sale to cover taxes</b> associated with vesting equity awards."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Takeda (TAK) report for CEO Julie So-Young Kim?

Takeda reported that CEO Julie So-Young Kim sold 89,090 American Depositary Shares on August 10, 2026. The company describes this as a mandatory sale to cover taxes arising from the vesting of her equity awards.

At what price were the Takeda (TAK) shares sold by the CEO?

The reported sale by Takeda’s CEO used a weighted average price of $17.10 per share. A footnote explains she can provide full details on the number of shares sold at each separate price within the disclosed ranges upon request.

How many Takeda (TAK) shares does the CEO hold after this Form 4 sale?

After the reported transaction, Takeda’s CEO holds 391,489 American Depositary Shares directly. This figure reflects her position following the 89,090-share sale made to satisfy tax obligations tied to equity award vesting.

Was the Takeda (TAK) CEO’s share sale related to a 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. Instead, a footnote states the transaction was a mandatory sale to cover taxes from vesting equity awards, rather than a discretionary trading-plan sale.

What type of security did the Takeda (TAK) Form 4 transaction involve?

The transaction involved American Depositary Shares of Takeda Pharmaceutical Co Ltd. These ADS represent the company’s equity for U.S. investors and were sold in an open market or private transaction according to the Form 4 code description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Julie So-Young

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		89,090	D	$17.1(2)	391,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Julie S Kim	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)